FCF $3.8b — solid, comfortably covers operations and capital return
Rev+9.3%TTM YoYB
Revenue +9.3% — at or above S&P median
D/E0.09B+
D/E 0.09 — below the Healthcare debt median (≈40th pctile)
P/E20.7xB+
P/E 20.7 — below the Healthcare median (≈40th pctile)
PEG1.38B
PEG 1.38 — acceptable premium for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 64
Quality66.3
Growth78.6
Value50.4
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week high
1% off the 12-month high
vs DCF fair value24% aboveest. fair value ~$673
What the price assumes: free cash flow compounding at ~14% a year for the next decade — vs the ~13% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability36% · B+gross profit ÷ total assets (Novy-Marx)
ROIC8.6% · Breturn on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Regeneron’s EYLEA franchise, the market‑leading anti‑VEGF injection for wet AMD and diabetic macular edema, continues to generate cash at a scale that fuels compounding growth – free cash flow of $3.8B on a $85.3B market cap yields a 4.5% FCF return while revenue still climbs 9.3% YoY. The Bull Rankings model awards REGN a Quality‑Growth score of 64, with Growth as its strongest pillar (79) underscoring the durability of its pipeline, and the stock trades at a forward P/E of 20.5, already pricing in the reverse‑DCF implied 14% FCF growth—well above the 9.3% revenue pace, meaning the upside hinges on sustaining that premium growth. The thesis rests on EYLEA’s entrenched payer relationships and the ability to expand indications, which should keep the compounding engine humming.
Moat
EYLEA’s long‑acting intravitreal delivery and extensive clinical data create a high switching cost for ophthalmologists, locking in a sizable share of the market for wet age-related macular degeneration and diabetic macular edema. REGN’s low debt‑to‑equity of 0.09 and a ROE of 13.7% reflect efficient capital use, while its proprietary antibody platform underpins a pipeline that competitors cannot replicate quickly, preserving margin strength at a profit margin of 27.9%.
Risk
The premium valuation is fragile: a forward P/E of 20.5 is high for a biotech with revenue growth slipping to only 9.3% YoY, and any slowdown in EYLEA sales or failure to launch new indications would force the price toward the 52‑week low of $541. A bear‑case trigger is a miss on the next quarterly earnings that pushes the implied 14% FCF growth below the historical revenue trend, prompting analysts to cut the consensus target.
Horizon
1-3 yr $840.43 (27-analyst consensus) — fundamentals + valuation re-rating. 5 yr $1,230 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $1,825 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
REGN vs the Top Picks average
Pillar
REGN
Book avg
Diff
Quality
0.66
0.84
-0.17
Growth
0.79
0.87
-0.09
Value
0.50
0.76
-0.25
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · REGN
Trend
-2.9 over 48 daily scores
From 66.9 (Jun 22) → 64.0 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
30-day change
+11.0%
90-day change
+12.7%
Forward EPS estimate
$60.61
Over the last 90 days, what analysts expect REGN to earn is materially higher (+12.7%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Position sizing · REGN
$
%
%
Shares to buy
2
Position size
$1,671
3.3% of portfolio
Stop price
$626.50
25% below $835.34
$ at risk if stopped
$417.67
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Regeneron Pharmaceuticals, Inc. (REGN): score, valuation & FAQ
Regeneron Pharmaceuticals, Inc. (REGN) is a Biotechnology company that scores 64 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (B+) and P/E (B+). On valuation, REGN sits about 24% above our discounted-cash-flow fair value — the current price implies roughly 14% annual free-cash-flow growth over the next decade.
Is REGN a good stock to buy?
Bull Rankings scores REGN 64 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by D/E (B+) and P/E (B+). A score is a quantitative screen of Regeneron Pharmaceuticals, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does REGN score 64 on Bull Rankings?
The score is carried by growth at 78.6 out of 100, and held back by value at 50.4 — the three pillars combine geometrically, so a weak one cannot be papered over by a strong one. REGN earns its highest marks on D/E (B+) and P/E (B+). Each signal is graded against sector-aware thresholds rather than one absolute bar, so REGN is measured against Biotechnology peers, not against the market as a whole.
Is REGN overvalued or undervalued?
Based on $835.34, REGN sits about 24% above our discounted-cash-flow fair value — the current price implies roughly 14% annual free-cash-flow growth over the next decade. It trades at a 20.7x P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in REGN?
The premium valuation is fragile: a forward P/E of 20.5 is high for a biotech with revenue growth slipping to only 9.3% YoY, and any slowdown in EYLEA sales or failure to launch new indications would force the price toward the 52‑week low of $541. A bear‑case trigger is a miss on the next quarterly earnings that pushes the implied 14% FCF growth below the historical revenue trend, prompting analysts to cut the consensus target.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.